BOSTON, Mass. – Tuberculosis (TB) is often overlooked in developed countries such as the United States, but this bacterial infection remains one of the deadliest diseases globally and results in millions of deaths annually. Deaths can occur even with treatment, sometimes because of drug resistance in TB bacteria and other...
Latest News
Baton Rouge, Louisiana – Diabetes affects more than 1 in 10 — or more than 38 million — Americans. People with diabetes who keep their blood sugar levels in the near-normal range generally have a much lower risk of developing diabetes complications such as heart, kidney, and eye diseases. The...
ITHACA, N.Y. – Scientists have long believed that a newborn’s immune system was an immature version of an adult’s, but new research from Cornell University shows that newborns’ T cells – white blood cells that protect from disease – outperform those of adults at fighting off numerous infections. These results...
Boston, Mass. – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear cell...
Charleston, SC – A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity. Medulloblastoma is the most common malignant brain tumor in children. Survival rates vary according to which one of the...
Two biotechs are shoring up their pipelines and commercial aspirations, tacking on a clinical-stage rare disease drug and a preclinical cancer med, respectively. Fortress Biotech-founded Avenue Therapeutics is adding on a phase 1/2-stage asset from AnnJi Pharmaceutical for the treatment of spinal and bulbar muscular atrophy (SBMA). Financial details are...
Grenoble. France – Researchers from the Bhogaraju Group at EMBL Grenoble have gained new insights into how a cancer-relevant family of proteins bind their targets. The results of the study, published in The EMBO Journal, could potentially help in the development of drugs against certain chemotherapy- and radiotherapy-resistant cancers. The...
Seattle, WA – A new lab assay developed by researchers at Fred Hutch Cancer Center could make diagnosis and treatment of small cell lung cancer and non-small cell lung cancer easier. The blood-based test, also called a “liquid biopsy,” can detect differences between types of lung cancer by examining patterns...
Washington, DC – A 10-minute virtual reality (VR) session significantly lessened pain in hospitalized patients with cancer in a recent clinical trial published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. Even a day later, participants experienced sustained benefits. Most people with cancer experience pain,...
Heidelberg, Germany – A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated with an ALK inhibitor – but the cancer cells quickly develop...